Education
About Us
Working with TipRanks
Follow Us
Sionna Therapeutics, Inc. (SION)
NASDAQ:SION
SION Stock Chart & Stats
$41.32
$0.55(1.26%)
At close: 4:00 PM EST
$41.32
$0.55(1.26%)
Day’s Range― - ―
52-Week Range$7.26 - $45.00
Previous CloseN/A
Volume33.51K
Average Volume (3M)255.12K
Market Cap
$1.84B
Enterprise Value$1.80B
Total Cash (Recent Filing)$248.33M
Total Debt (Recent Filing)$8.97M
Price to Earnings (P/E)―
Beta1.05
Next Earnings
Mar 19, 2026EPS Estimate
-0.54Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.46
Shares Outstanding44,628,788
10 Day Avg. Volume300,106
30 Day Avg. Volume255,122
Financial Highlights & Ratios
PEG Ratio-0.58
Price to Book (P/B)-6.74
Price to Sales (P/S)0.00
P/FCF Ratio-20.89
Enterprise Value/Market Cap0.98
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-7.30K
Enterprise Value/Ebitda-23.93
Forecast
1Y Price Target
$48.50Price Target Upside17.38% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering4
EPS Forecast (FY)-2.26
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical And Preclinical DataRobust preclinical evidence and favorable Phase one pharmacokinetic and safety results in healthy volunteers reduce development risk and support progression of Sionna's CF programs into patient studies.
Commercial Flexibility And CompatibilityPrograms engineered to act both as an add-on to standard therapy and as a standalone dual-combination regimen increase commercial pathways and may accelerate uptake if a cleaner safety profile is demonstrated.
Novel Mechanism PotentialNBD1 targeting directly stabilizes the CFTR domain altered by the common mutation, offering a distinct mechanism that could restore protein function beyond current modulators.
Bears Say
Entrenched CompetitionStrong incumbent franchises and entrenched market leadership by established competitors could limit market share gains for new entrants despite differentiated science.
Market Adoption FrictionPatient and caregiver burdens tied to monitoring requirements for switching therapies can slow overall adoption of new treatments and may delay uptake for novel entrants even if they offer clinical advantages.
Translational Risk From Surrogate AssaysDependence on an in vitro CF HBE assay to set dose and exposure targets creates risk because clinical proof of translation is required; failure of proof-of-concept readouts to confirm predicted benefits would be a material setback.
Sionna Therapeutics, Inc. News
SION FAQ
What was Sionna Therapeutics, Inc.’s price range in the past 12 months?
Sionna Therapeutics, Inc. lowest stock price was $7.25 and its highest was $45.00 in the past 12 months.
What is Sionna Therapeutics, Inc.’s market cap?
Sionna Therapeutics, Inc.’s market cap is $1.84B.
When is Sionna Therapeutics, Inc.’s upcoming earnings report date?
Sionna Therapeutics, Inc.’s upcoming earnings report date is Mar 19, 2026 which is in 41 days.
How were Sionna Therapeutics, Inc.’s earnings last quarter?
Sionna Therapeutics, Inc. released its earnings results on Nov 05, 2025. The company reported -$0.46 earnings per share for the quarter, beating the consensus estimate of -$0.484 by $0.024.
Is Sionna Therapeutics, Inc. overvalued?
According to Wall Street analysts Sionna Therapeutics, Inc.’s price is currently Undervalued.
Does Sionna Therapeutics, Inc. pay dividends?
Sionna Therapeutics, Inc. does not currently pay dividends.
What is Sionna Therapeutics, Inc.’s EPS estimate?
Sionna Therapeutics, Inc.’s EPS estimate is -0.54.
How many shares outstanding does Sionna Therapeutics, Inc. have?
Sionna Therapeutics, Inc. has 44,628,788 shares outstanding.
What happened to Sionna Therapeutics, Inc.’s price movement after its last earnings report?
Sionna Therapeutics, Inc. reported an EPS of -$0.46 in its last earnings report, beating expectations of -$0.484. Following the earnings report the stock price went down -1.571%.
Which hedge fund is a major shareholder of Sionna Therapeutics, Inc.?
Currently, no hedge funds are holding shares in SION
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Sionna Therapeutics, Inc. Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$48.50 (17.38% Upside)
$48.50 (17.38% Upside)
Blogger Sentiment
Bullish
SION Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 116.9K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $32.2M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 6.2%
Last 30 Days ▼ 0.3%
Last 30 Days ▼ 0.3%
Fundamentals
Return on Equity
-28.07%
Trailing 12-Months
Asset Growth
71.99%
Trailing 12-Months
Company Description
Sionna Therapeutics, Inc.
Sionna Therapeutics, Inc. is a biopharmaceutical company. The Company provides treatment paradigm for cystic fibrosis patients by developing medicines that normalize the function of the cystic fibrosis transmembrane conductance regulator.
SION Stock 12 Month Forecast
Average Price Target
$48.50
▲(17.38% Upside)
Technical Analysis
Stoke Therapeutics
―
Vir Biotechnology
―
Immatics
―
Tango Therapeutics
―
Amylyx Pharmaceuticals Inc
―